Alvotech Appoints Interim Chief Quality Officer : vimarsana.

REYKJAVIK, Iceland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join its corporate leadership team as interim Chief Quality Officer. Christina succeeds Sandra Casaca, who is leaving the company as a part of other organizational changes. Christina Siniscalchi has for over ten years served in senior quality positions

Related Keywords

Ukraine , Hong Kong , Japan , Singapore , Yangtze River , China General , China , Indonesia , Australia , Canada , New Zealand , Taiwan , Israel , Iceland , Switzerland , Vietnam , Republic Of , Reykjavik , C10 , South Korea , Philippines , Pakistan , Malaysia , Thailand , Cambodia , United States , United Kingdom , Bangladesh , India , Robert Wessman , Sandra Casaca , Christina Siniscalchi , Saval Latin America , Africa , Kamada Ltd , Teva Pharmaceuticals , Pharma Corporation Canada , Yangtze River Pharmaceutical Group Co Ltd , Temple University , Alvotech Holdings , Norwich Pharmaceuticals , Regulatory Affairs , Mallinckrodt Pharmaceuticals , Georgia Institute Of Technology , Teva Pharmaceutical Industries Ltd , Fuji Pharma Co Ltd Japan , Lotus Pharmaceuticals Co Ltd , Oaktree Acquisition Corp , Chief Quality , Quality Assurance , Applied Biology , Georgia Institute , South America , Teva Pharmaceutical Industries , Advanz Pharma , Cipla Med Pro , Yangtze River Pharmaceutical , Middle East , North Africa , Abdi Ibrahim , Mega Labs , Latin America , Private Securities Litigation Reform Act , Oaktree Acquisition , Note Regarding Forward Looking ,